ResearcherStony Brook UniversityNo recent work listed

Chi Chun Wong

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1362-3541; OpenAlex author ID A5024721864. Sources: OpenAlex.

Their work

Papers: 2 (first author 1, last author 0)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2014: 1 paper · 2015: none · 2016: none · 2017: none · 2018: none · 2019: none · 2020: 1 paper

Papers 2

CircFOXK2 Promotes Tumor Growth and Metastasis of Pancreatic Ductal Adenocarcinoma via Complexing with RNA Binding Proteins and Sponging MiR-942 Co-author DOI 10.1016/j.pan.2020.07.369 ↗
Phospho-sulindac inhibits pancreatic cancer growth: NFATc1 as a drug resistance candidate. First author DOI 10.3892/ijo.2013.2190 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Yuanfeng Chen · 1 shared paper, 2020 · strength 0.13
- Paper CircFOXK2 Promotes Tumor Growth and Metastasis of Pancreatic Ductal Adenocarcinoma via Complexing with RNA Binding Prot… DOI 10.1016/j.pan.2020.07.369 ↗
Ut Kei Lou · 1 shared paper, 2020 · strength 0.13
- Paper CircFOXK2 Promotes Tumor Growth and Metastasis of Pancreatic Ductal Adenocarcinoma via Complexing with RNA Binding Prot… DOI 10.1016/j.pan.2020.07.369 ↗
Basil Rigas · 1 shared paper, 2014 · strength 0.06
- Paper Phospho-sulindac inhibits pancreatic cancer growth: NFATc1 as a drug resistance candidate. DOI 10.3892/ijo.2013.2190 ↗
Onika T. Murray · 1 shared paper, 2014 · strength 0.06
- Paper Phospho-sulindac inhibits pancreatic cancer growth: NFATc1 as a drug resistance candidate. DOI 10.3892/ijo.2013.2190 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.